Neurotransmitters are chemical substances; signals are transmitted from the neuron to the target cell via a synapse via neurotransmitters. Neurotransmitters are associated in synaptic vesicles gathered in the presynaptic membrane and are released into the synaptic cleft, in the synaptic cleft they attach to receptors in the postsynaptic membrane. (1) Monoamine transporters are proteins found on the nerve terminals of noradrenogenic, serotonergic, and dopaminergic neurons. They are also part of the sodium-dependent transporters and have a key role in terminating the action of neurotransmitters released into the synaptic cleft. Furthermore, transporter proteins are important in the assimilation of monoaminergic innervations as well as being the main target molecules for numerous quantities of antidepressant drugs and substances of abuse. Monoamine transporters consist of vesicular monoamine transporters (VMATs) and the plasma membrane. Monoamine is transported into the vesicles by the latter non-selectively, while dopamine, adrenaline and serotonin are transported into the vesicles by Na+/Cl- and selectively by the former. The transport of monoamines in the cytoplasm is inhibited when antiepileptic drugs, for example SSRIs, are linked to the adrenaline transporter (NET) or the dopamine transporter (DAT) and the serotonin transporter (SERT). Therefore the monoamine level increases in the synaptic cleft. Monoamine transporters are the site of action of drugs, (2) Affective diseases such as schizophrenia or Parkinson's disease may be involved due to functional changes in the transporters. Neurotransmitter transporters are proven to be the most important targets for central nervous system drug discovery, (3) mainly for antidepressant drugs. Antidepressants act as inhibitors of monoamine transporters. Serotonin se...... half of the paper ......ion and the evidence demonstrated in this study was due to the low concentration of homovanillic acid which is a metabolite of dopamine (6). Dopamine agonists such as ropinirole, bromocriptine exhibit antidepressant characteristics. Amineptine is a TCA derivative that also blocks dopamine reuptake and exhibits noradrenergic and serotonergic activity. Most existing antidepressants appear to show similar efficacy in the general treatment of depression, however, antidepressants that have different action profiles may more effectively target particular symptoms of depressive syndrome. In such cases, the treatment provided may be carefully focused on the predominant or determining symptomatology for a specific patient. Studies have shown that this treatment method has the potential to improve response and remission rates.(6)